No synergism between bis(Propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson’s disease mice

Cheng You Zheng, Bao Jian Guo, Wei Cai, Wei Cui, Shing Hung Mak, Yu Qiang Wang, Simon Ming Yuen Lee, Yi Fan Han, Zai Jun Zhang

Research output: Journal article publicationJournal articleAcademic researchpeer-review

1 Citation (Scopus)


Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra. However, the neuroprotective effects of co-treatment were not significantly improved when compared with those of B3C or rasagiline alone. Collectively, we have demonstrated that B3C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.
Original languageEnglish
Pages (from-to)1339-1346
Number of pages8
JournalNeural Regeneration Research
Issue number8
Publication statusPublished - 1 Aug 2016


  • Bis(propyl)-cognitin
  • Dopamine
  • Monoamine oxidase B
  • Multitarget
  • Nerve regeneration
  • Neural regeneration
  • Neuroprotection
  • Parkinson’s disease
  • Rasagiline
  • Synergism

ASJC Scopus subject areas

  • Developmental Neuroscience

Cite this